-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Healthcare Investment in Asia: Who, What, Where and Why?
May 15, 2018
The Asia Pacific healthcare deal market is vibrant. Deal flow climbed to about 770 in 2017, up 74 percent from 442 the previous year, according to S&P Capital IQ data. Deal value increased to a net of USD$32 billion in 2017 (accounting for closed and cancelled deals) up from net $9.1 billion in 2016. Thus far 2018 appears on track to be another record-setting year.
Beyond the headline-grabbing numbers, what can we learn from the transactions market? Here are a few observations:
- Buyers: In recent years private equity investors have emerged as important players in the transaction landscape, for example KKR’s purchase of Laser One. However, most transactions still involve corporate buyers. Private equity tends to focus on Japan and Australia while family owned companies and conglomerates dominate Southeast Asian markets. China remains a hybrid PE and corporate market, especially in the hospitals segment.
- Deal Theme: Investment themes are migrating from pursuing standalone opportunities to creating platform-shaping transactions, such as hospital networks; diagnostics centers; dental clinics; and cancer treatment centers. A recent example: C&C Incubator’s Qingdao Meinian Health Technology deal designed to build scale and achieve regional consolidation in the healthcare record-management software market.
- Targeted Asset Mix: Hospital, pharmacy and service-related transactions have become the most attractive assets. What began as a subtle shift a few years ago and is now a norm: Asia investors are targeting healthcare services rather than molecules. As demographic shifts occur across Asia, expect to see more deals focused at the extreme ends of the life spectrum, for example fertility clinics at one end and home nursing and elder care transactions (such as Keihan Life Support) at the other.
- Transaction Size: The average deal size is getting smaller at USD$56 million over the past 12 months versus USD$67 million for the prior three-year period. This is because of the recent focus on rollups of multiple smaller companies instead of pursuing large single transactions.
- Geography: Traditionally, investors focused on building a competitive position within a few country markets, e.g. Japan, Korea and Australia. As investor capability, knowledge of regional competitive dynamics, patient needs and healthcare provider behavior has increased, confidence in structuring cross-border deals has grown, driven by operating model fungibility.
Looking forward, we anticipate that in 2018-2023 deal flow will continue to increase as more investors enter Asia’s health markets. Growth drivers include expanding household income; more public-sector spending; the infusion of IT services into care models; and aging populations.
For new or existing investors, the key questions are where to participate and how to win. A range of opportunities exist in analytics, solutions, support and systems (laboratory services, micro-hospitals, retail pharmacies, visiting nurses, hospital outsourcing, etc.). Given the plethora of shiny opportunities, investors need to carefully consider their overall strategy and dig deep in due diligence. Not all that glitters is gold.
Contributor:
- Shriharsha Sarkar
Principal, Consulting Services Asia